Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
The Journal. · The Wall Street Journal & Spotify Studios
May 21, 202519m 12s
Audio is streamed directly from the publisher (pdst.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.
Further Listening:
Why WeightWatchers Wants in on Drugs Like Ozempic
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices